ANGLE plc appoints James M. Reuben as Scientific Advisor
June 03 2015 - 7:00AM
Business Wire
MD Anderson researcher is a leader in the field
of circulating tumor cells
ANGLE plc (AIM:AGL OTCQX:ANPCY), a medical diagnostics company
with pioneering products for cancer diagnostics and fetal health,
is pleased to announce the appointment of James M. Reuben, PhD,
MBA, as a Scientific Advisor to the company with immediate
effect.
Dr. Reuben is a Professor in the Department of Hematopathology,
Division of Pathology/Lab Medicine at The University of Texas MD
Anderson Cancer Center, Houston, Texas. He has conducted
significant research on circulating tumor cell subsets, including
those with epithelial and mesenchymal phenotypes and their clinical
relevance to minimal residual disease in breast cancer.
The University of Texas MD Anderson Cancer Center is one of the
world’s most respected centres devoted exclusively to cancer
patient care, research, education and prevention. A different part
of MD Anderson is already working with ANGLE as a key opinion
leader in the field of colorectal cancer.
Related publications include "Circulating tumor cells, disease
progression, and survival in metastatic breast cancer" in the New
England Journal of Medicine; "Circulating tumour cells are
associated with increased risk of venous thromboembolism in
metastatic breast cancer patients" in the British Journal of
Cancer; and "Circulating tumor cells in metastatic inflammatory
breast cancer" published in the Annals of Oncology.
Dr. Reuben received his PhD in immunology from McGill University
in Montreal, Canada and his MBA from University of Houston,
Houston, Texas. He completed his research fellowship in the
Department of Experimental Therapeutics at The University of Texas
MD Anderson Cancer Center with Evan M. Hersh, MD and Emil J
Freireich, MD, as mentors.
For the past 30 years, Dr. Reuben has been a member of the
American Association for Cancer Research (AACR), and the American
Society of Clinical Oncology (ASCO). He has also been a member of
the American Society of Hematology since January, 2000.
ANGLE is currently commercializing the Parsortix system, a cell
separation technology that enables a simple blood test to capture
targeted cells, such as circulating tumor cells (CTCs) for
molecular profiling and analysis. Parsortix can help deliver
targeted cancer diagnostics designed to inform personalized
treatment of cancer. It is also designed to be compatible with
existing major medtech analytical platforms and to act as a
companion diagnostic for major pharma in helping to identify
patients that will benefit from a particular drug and then
monitoring the drug’s effectiveness.
ANGLE has established formal collaborations with world-class
cancer centers and is working with these cancer centers to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. In addition to cancer cells,
the Parsortix technology has the potential for deployment for other
clinically significant cell types in the future.
"Jim Reuben has exceptional knowledge of circulating tumor
cells. He was one of the leading investigators in the earliest
studies on CTCs and has been very actively involved ever since,"
said Andrew Newland, Founder and CEO of ANGLE. "We are delighted
that he has joined ANGLE’s Scientific Advisory Board and believe
his in-depth knowledge and understanding of CTCs and wide network
of contacts in the field will be of great benefit to ANGLE as we
drive towards the widespread adoption of the Parsortix system in
cancer care."
About ANGLE plc
ANGLE is a UK-based specialist medtech company commercializing
the Parsortix system, a cell separation technology that enables a
simple blood test to capture targeted cells for investigation, such
as circulating tumor cells (CTCs) for molecular profiling and
analysis. Parsortix can help deliver targeted cancer diagnostics
that has the potential to inform personalized treatment of cancer.
It is also designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug’s effectiveness. ANGLE
has established formal collaborations with world-class cancer
centers and is working with these cancer centers to demonstrate key
applications for its Parsortix non-invasive cancer diagnostic
system as a liquid biopsy. In addition to cancer cells, the
Parsortix technology has the potential for deployment for other
clinically significant cell types in the future.
ANGLE is a public company trading on the AIM market of the
London Stock Exchange under the ticker symbol AGL and on the OTCQX
market in the US under the ticker symbol ANPCY. For more
information, www.angleplc.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150603005268/en/
ANGLE plcPeggy Robinson, 914-525-5928Vice
PresidentorMedia:Brandwidth Solutions LLCDebra Harrsch,
267-577-0806dharrsch@brandwidthsolutions.com
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024